Meridian Bioscience Inc (NASDAQ:VIVO)
| 26.44 Delayed Data As of Aug 05 |  +0.95 / +3.73%Today’s Change | 5.51 Today|||52-Week Range 26.51 | +170.57% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.0B |
Company Description
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
Contact Information
Meridian Bioscience, Inc. 3471 River Hills Drive Cincinnati Ohio 45244 |
Employees
Shareholders
| Individual stakeholders | 5.46% |
| Mutual fund holders | 46.65% |
| Other institutional | 36.62% |
Top Executives
| John Patrick Kenny | President, CEO & Executive Director |
| Bryan T. Baldasare | Chief Financial Officer, Treasurer & Secretary |
| Lourdes Weltzien | Executive Vice President-Life Science |
| Tony Serafini-Lamanna | Executive Vice President-Diagnostics |
| Melissa J. McCarey | Vice President-Global Human Resources |
